Micro Doses, Macro Potential? Considerations for Microdosing Tirzepatide in Multi‐Dose Pens
Obesity June 4, 2026 Abigail B. Lodrigues, Alissa V. Russell, Shelby Tungate Lopez et al.
A.M.K. has received advisory/consulting fees from Camurus Pharmaceuticals, Dexcom Inc., Eli Lilly and Company, and Lexidrug/Wolters-Kluwer. A.B.L., A.V.R., and S.T.L. declare no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.